Johns Hopkins Medicine. Associate Professor, Cardiology. Co-Editor in Chief @AJPCardio. #WomenHeartHealth #CardioObstetrics #cvPrev #echofirst She/her #BeKind
Jul 17, 2021 • 4 tweets • 6 min read
Now up, growing your program through modern media by @purviparwani. In current era, #SoMe is a powerful tool for growing your program. #SCCT2021
Strategies for growing your growing your advanced imaging program through modern media. Great talk by @purviparwani#SCCT2021
Jul 17, 2021 • 4 tweets • 6 min read
#YesCCT : Clinical reporting & understanding finance by @docjuanb at #SCCT2021 . There are reimbursement challenges . #Cardiac CT is in the wrong Ambulatory Payment Classification (APC). Bill also must be supported by clinical symptom & diagnostic ICD10 codes. Not a “rule out”.
Reimbursement tracks with the CPT used so use the right CPT code and make sure language in report supports that code. All CTA assumes 3D, thus need to mention 3D in report. Have your reporting align with @Heart_SCCT guidelines. @docjuanb at #SCCT2021
Obstructive CAD is just one etiology of ischemia. If no obstructive disease, consider coronary microvascular dysfunction #CMD. So what is best imaging modality for CMD? @VTaqMD#SCCT2021
How to evaluate for #CMD? A multidimensional cardiac stress PET test can evaluation for perfusion, function, and coronary blood flow. @VTaqMD#SCCT2021
Jul 16, 2021 • 5 tweets • 6 min read
Patients with #MINOCA were more likely to be women and have fewer traditional CV risk factors. Heterogenous pathophysiology – etiology is of great importance to guide treatment. Inge van den Hoogen #SCCT2021#MINOCA diagnosis. Overt non-cardiac disorders need to be excluded. Also need to rule out missed obstruction and non-ischemic causes of myocardial injury. Then after MINOCA diagnosed, need to workup etiology. Inge van den Hoogen #SCCT2021
Jul 16, 2021 • 6 tweets • 9 min read
Women are not smaller men! #Atherosclerosis genesis, progression & sequelae different in women. Plaque erosion causing ACS more common in women. Women have unique #SDOH, are undertreated with #cvPrev therapies & #GDMT, leads to worsening outcomes in women. @lesleejshaw#SCCT2021
Women’s CVD risk can be underestimated. Female specific risk enhancers help. #CAC if risk uncertain. Women have lower #CAC prevalence than men but prevalence increases after menopause. CAC when present confers greater risk of incident CVD in women than men. @lesleejshaw#SCCT2021